Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System

Artivion (NYSE:AORT) announced U.S. FDA approval of the NEXUS Aortic Arch System on April 7, 2026, developed by partner Endospan.

Rhea-AI Summary

Artivion (NYSE:AORT) announced U.S. FDA approval of the NEXUS Aortic Arch System on April 7, 2026, developed by partner Endospan. The approval allows Artivion to exercise an option to acquire Endospan within 90 days.

Artivion has a $150 million delayed draw term loan in place to fund a potential acquisition. FDA support comes from the TRIOMPHE IDE trial showing 90% patient survival from lesion-related death, 90% freedom from disabling stroke at 1 year, and 98% freedom from reintervention due to endoleaks at 1 year.

Positive

• FDA approval granted for NEXUS aortic arch system
• Artivion 90-day option to acquire Endospan
• TRIOMPHE trial: 90% survival from lesion-related death at 1 year
• TRIOMPHE trial: 90% freedom from disabling stroke at 1 year
• TRIOMPHE trial: 98% freedom from reintervention at 1 year
• $150 million financing secured to fund potential acquisition

Negative

• $150 million delayed draw term loan increases potential leverage
• Acquisition decision must occur within 90 days, creating timing pressure

Argus Apr 7 session

+5.29% close to close 2.5x rel. volume Open Argus

Details

News Market Reaction – AORT

On Apr 7, the day this news came out, AORT closed 5.29% above the previous close. That session’s volume was 2.5x the stock’s average daily volume.

Data tracked by StockTitan Argus for the Apr 7 session.

Key Figures

Delayed draw term loan: $150 million PMA approval: NEXUS Aortic Arch System Option exercise window: 90 days +3 more

Delayed draw term loan

$150 million

Facility secured to fund potential Endospan acquisition

PMA approval

NEXUS Aortic Arch System

U.S. FDA premarket approval granted

Option exercise window

90 days

Period to exercise option to acquire Endospan after FDA notice

Survival from lesion-related death

90%

At 1 year in NEXUS TRIOMPHE IDE trial

Freedom from disabling stroke

90%

At 1 year in NEXUS TRIOMPHE IDE trial

Freedom from reintervention due to endoleaks

98%

At 1 year in NEXUS TRIOMPHE IDE trial

Previous Fda approval Reports

1 past event · Latest: Dec 09

Same Type 1 event

1. Dec 09

   Regulatory approval

   24h Move

   -2.2%

   FDA Humanitarian Device Exemption for AMDS Hybrid Prosthesis with strong trial data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pma, endovascular stent graft, aortic arch, chronic aortic dissections, +3 more

7 terms

pma regulatory

"the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA)"

PMA stands for Premarket Approval, the U.S. Food and Drug Administration’s highest-level review for high-risk medical devices. It’s a thorough evaluation to confirm a device is safe and effective before it can be sold, like a final safety inspection and license to operate. Investors care because receiving PMA can open a significant revenue stream, while delays or rejection can postpone sales and reduce a company’s value.

endovascular stent graft medical

"NEXUS is a branched endovascular stent graft system approved in the United States"

A soft metal framework covered by a fabric tube that is delivered inside a damaged blood vessel to shore up the wall and restore normal blood flow, like installing an inner sleeve to patch a leaking pipe from the inside. Investors watch this device because its safety, ease of use, regulatory approval, reimbursement and long-term durability drive procedure volumes, company sales and potential liability or replacement costs in the medical-device market.

aortic arch medical

"NEXUS Aortic Arch System, developed by Endospan Ltd."

The aortic arch is the curved top portion of the body's main artery that carries blood from the heart and branches off to supply the brain, arms and upper body — think of it as a highway interchange where major roads split from the main route. It matters to investors because diseases, injuries or surgeries involving the aortic arch often require specialized drugs, devices or procedures that drive clinical trials, regulatory reviews, revenue opportunities and potential liability for companies in healthcare and medical technology.

chronic aortic dissections medical

"treatment of aortic arch disease, including chronic aortic dissections, a patient population"

A chronic aortic dissection is a long-lasting tear in the inner wall of the body's main artery (the aorta) that lets blood split the wall and form a false channel, weakening the vessel over time. Like a split in a garden hose that creates a second, unstable pathway for water, it can reduce normal blood flow and raise the risk of rupture or heart strain, which matters to investors because it drives demand for long-term medical devices, drugs, hospital services, and regulatory scrutiny.

ide trial medical

"The FDA's approval is supported by data from the NEXUS TRIOMPHE IDE trial"

An IDE trial is a regulated clinical study that lets a company test a medical device in patients under an Investigational Device Exemption from the U.S. regulator; it’s essentially a formal permit to gather safety and effectiveness data before broad commercial approval. For investors, an IDE trial is a major de-risking step and milestone—successful results move a device closer to market approval and revenue, while delays or negative outcomes can materially affect a company’s value, similar to how a road-test permit lets a car maker prove a new model is safe before mass production.

endoleaks medical

"98% freedom from reintervention due to endoleaks at one year in a high-risk patient population"

An endoleak is persistent blood flow into the bulging sac of a repaired blood vessel after a minimally invasive aneurysm repair using a tubular implant (stent graft). It's like patching a leaking tire but finding that air still seeps into the patched area; the aneurysm may continue to be at risk of rupture unless the leak is fixed. This matters to investors because endoleaks drive follow-up procedures, device recalls or design changes, regulatory scrutiny, and additional healthcare costs that affect a medical device maker's revenue and reputation.

term loan financial

"Artivion has a $150 million delayed draw term loan in place"

A term loan is a type of loan that is borrowed for a set period of time, with a fixed schedule for repaying the money, usually in regular payments. It matters to investors because it represents a company's borrowing costs and financial stability; reliable repayment of these loans can indicate strong financial health, while difficulties may signal potential risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Endospan's NEXUS branched endovascular stent graft system shown to effectively treat aortic arch disease, including chronic aortic dissections

ATLANTA, April 7, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the NEXUS® Aortic Arch System, developed by Endospan Ltd. ("Endospan"), Artivion's long-standing partner. The approval entitles Artivion to exercise its option to acquire Endospan at any time within 90 days of receiving this notice of FDA approval. Artivion has a $150 million delayed draw term loan in place, secured in anticipation of this approval, to fund a potential acquisition. The Company is actively working to complete its evaluation of the option following the earlier than anticipated approval.

NEXUS is a branched endovascular stent graft system approved in the United States for the minimally invasive treatment of aortic arch disease, including chronic aortic dissections, a patient population that has historically had little treatment option but open-chest surgery. The FDA's approval is supported by data from the NEXUS TRIOMPHE IDE trial, which demonstrated 90% patient survival from lesion-related death, 90% freedom from disabling stroke at 1-year post treatment, and 98% freedom from reintervention due to endoleaks at one year in a high-risk patient population.

"NEXUS receiving FDA approval ahead of our expectations is an exciting milestone for patients with aortic arch disease, for our partner Endospan, and for Artivion," said Pat Mackin, Chairman, President, and Chief Executive Officer. "The TRIOMPHE data has consistently demonstrated the clinical value of this technology, and we are proud to have supported Endospan on this journey. We have proactively put the financing in place to support a potential acquisition, and we are moving diligently to finalize our considerations around the option. We look forward to updating shareholders soon."

About Artivion, Inc.

Headquartered in suburban Atlanta, Georgia, Artivion, Inc., is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com.

About Endospan Ltd.

Privately held Endospan, headquartered in Herzliya (Tel Aviv), Israel, is a pioneer in the endovascular repair of Aortic Arch Disease including aneurysms and dissections. Endospan has received CE-Mark to commercialize in Europe the NEXUS Stent Graft System, the first endovascular off-the-shelf system to treat Aortic Arch Disease which affects a greatly underserved group of patients diagnosed with a dilative lesion in, or near, the aortic arch. While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA), Aortic Arch Disease patients with aneurysms or dissections have not been as fortunate and have had little choice but to undergo open-chest surgery with its invasiveness and risks, lengthy hospitalization periods, and prolonged recuperation. For additional information about Endospan, visit their website, www.endospan.com.

Contact:

Artivion	Gilmartin Group LLC
Lance A. Berry	Brian Johnston
Executive Vice President,	Phone: 332-895-3222
Chief Operating Officer &	investors@artivion.com
Chief Financial Officer
Phone: 770-419-3355

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-announces-us-fda-approval-of-the-nexus-aortic-arch-system-302735203.html

SOURCE Artivion, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Artivion (AORT) announce on April 7, 2026 about NEXUS FDA approval?

Artivion announced FDA approval of the NEXUS Aortic Arch System on April 7, 2026. According to Artivion, the approval allows the company to exercise an option to acquire Endospan within 90 days.

What clinical results supported the NEXUS FDA approval for Artivion (AORT)?

The TRIOMPHE IDE trial showed strong 1-year outcomes: 90% survival, 90% freedom from disabling stroke, and 98% freedom from reintervention. According to Artivion, these results supported FDA approval.

How will Artivion fund a potential acquisition of Endospan after NEXUS approval (AORT)?

Artivion has a $150 million delayed draw term loan arranged to fund a possible acquisition. According to Artivion, this financing was secured in anticipation of FDA approval.

What is the deadline for Artivion (AORT) to exercise the option to buy Endospan?

Artivion may exercise its acquisition option within 90 days of receiving FDA approval. According to Artivion, the company is actively evaluating the option following earlier-than-expected approval.

What investor risks should shareholders consider after Artivion's (AORT) NEXUS approval?

Key risks include potential increased leverage if the $150 million loan is drawn and timing pressure from the 90-day option window. According to Artivion, the company is evaluating the acquisition option.